Stock Events

Stock Events

Trevena 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6T4.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.78B
ACADIA Pharmaceuticals competes with Trevena in the development of central nervous system therapies, including treatments for pain and other conditions Trevena targets.
Alkermes
ALKS
Mkt Cap5.81B
Alkermes competes in the area of central nervous system diseases, offering products that could be in direct competition with Trevena's pipeline.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division Janssen, develops medications that can compete with Trevena's offerings, especially in pain management.
Novartis
NVS
Mkt Cap297.32B
Novartis offers a broad range of healthcare solutions, including treatments for chronic pain and neurological conditions, areas Trevena is involved in.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap35.03B
Teva Pharmaceutical Industries is a key player in generic and specialty medicines, including pain management, directly competing with Trevena's market.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie has a strong presence in the neuroscience and pain management sectors, making it a competitor to Trevena's therapeutic focus.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb develops a wide range of prescription drugs, including those for conditions Trevena targets, making them competitors.
Pfizer
PFE
Mkt Cap161.09B
Pfizer's extensive portfolio in pain management and neurological disorders places it in direct competition with Trevena's product pipeline.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. offers innovative health solutions, including treatments for pain and neurological conditions, competing with Trevena.

About

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Show more...
CEO
Ms. Carrie L. Bourdow
Employees
23
Country
United States
ISIN
US89532E3071

Listings

STU
DE
6T4.STU
MU
DE
6T4.MU
OTC Link
US
TRVN

0 Comments

Share your thoughts

FAQ

What is Trevena stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Trevena stocks are traded under the ticker 6T4.MU.
How many employees does Trevena have?▼
As of April 11, 2026, the company has 23 employees.
In which sector is Trevena located?▼
Trevena operates in the Health & Wellness sector.
When did Trevena complete a stock split?▼
Trevena has not had any recent stock splits.
Where is Trevena headquartered?▼
Trevena is headquartered in Chesterbrook, United States.